Your browser is no longer supported. Please, upgrade your browser.
Settings
SRNE Sorrento Therapeutics, Inc. daily Stock Chart
SRNE [NASD]
Sorrento Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.72 Insider Own34.21% Shs Outstand182.61M Perf Week-25.00%
Market Cap1.05B Forward P/E- EPS next Y-0.93 Insider Trans0.06% Shs Float147.65M Perf Month122.37%
Income-249.20M PEG- EPS next Q-0.23 Inst Own16.40% Short Float16.39% Perf Quarter112.13%
Sales33.00M P/S31.96 EPS this Y-14.80% Inst Trans7.27% Short Ratio1.04 Perf Half Y225.00%
Book/sh0.55 P/B9.22 EPS next Y-5.00% ROA-44.50% Target Price- Perf Year42.82%
Cash/sh- P/C- EPS next 5Y37.00% ROE-322.50% 52W Range1.39 - 10.00 Perf YTD50.00%
Dividend- P/FCF- EPS past 5Y-11.10% ROI-91.30% 52W High-49.30% Beta2.73
Dividend %- Quick Ratio0.50 Sales past 5Y52.40% Gross Margin62.50% 52W Low264.75% ATR0.96
Employees310 Current Ratio0.60 Sales Q/Q26.20% Oper. Margin- RSI (14)63.53 Volatility31.24% 20.64%
OptionableYes Debt/Eq1.98 EPS Q/Q59.60% Profit Margin- Rel Volume2.04 Prev Close5.03
ShortableYes LT Debt/Eq1.81 EarningsMar 27 AMC Payout- Avg Volume23.35M Price5.07
Recom2.00 SMA2050.71% SMA5091.94% SMA20094.58% Volume47,709,400 Change0.80%
Oct-07-19Initiated JMP Securities Mkt Outperform $21
Jun-28-18Initiated B. Riley FBR, Inc. Buy $14.25
Jan-16-18Reiterated H.C. Wainwright Buy $20 → $30
May-22-17Reiterated Rodman & Renshaw Buy $30 → $20
May-22-17Reiterated FBR & Co. Outperform $13 → $9
Oct-03-16Initiated ROTH Capital Buy
Apr-06-16Reiterated FBR Capital Outperform $21 → $16
Mar-16-16Reiterated FBR Capital Outperform $22 → $21
Dec-22-15Initiated FBR Capital Outperform $22
Dec-07-15Resumed Rodman & Renshaw Buy $45
Aug-03-15Resumed MLV & Co Buy $34
Jul-29-15Reiterated Brean Capital Buy $17 → $26
May-28-15Initiated Brean Capital Buy $17
Mar-17-15Reiterated H.C. Wainwright Buy $13 → $20
Oct-02-14Initiated H.C. Wainwright Buy $11
Jun-19-14Initiated MLV & Co Buy $9
Dec-03-13Initiated Aegis Capital Buy $40
Nov-21-13Initiated CRT Capital Buy $11
May-23-20 09:15AM  Some wellness products growing over 1,000% during pandemic: Ro CEO Yahoo Finance
08:00AM  SORRENTO INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Sorrento Therapeutics, Inc. To Contact The Firm Newsfile
May-22-20 05:18PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sorrento Therapeutics, Inc. - SRNE GlobeNewswire
03:15PM  Day Trading Has Replaced Sports Betting as Americas Pastime. It Cant Support the Stock Market Forever. Barrons.com
May-21-20 07:00AM  Sorrento Enters Into Binding Term Sheet to Acquire Exclusive Rights to Abivertinib with Completed Registrational Trial Data in Non-Small Cell Lung Cancer GlobeNewswire -11.75%
May-20-20 01:18PM  Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More Zacks +5.17%
01:04PM  Short Sellers Challenge Sorrento's Announcement Of 100% Coronavirus Inhibition: 'Manipulative At The Worst Time' Benzinga
12:21PM  Why Sorrento Therapeutics Stock Is Sinking Again Today Motley Fool
11:52AM  Sorrento Therapeutics CEO: We are not a 'pump and dump' scheme Yahoo Finance
10:13AM  Sorrento Therapeutics CEO on focusing on the real deal antibody test rather than stock performance Yahoo Finance Video
07:02AM  Better Coronavirus Stock: Moderna vs. Sorrento Therapeutics Motley Fool
May-19-20 07:37PM  Here's Why Sorrento Therapeutics Dropped 16.6% Today Motley Fool -16.62%
07:02AM  Is Sorrento Therapeutics Stock a Buy After Its Promising Coronavirus News? Motley Fool
May-18-20 03:18PM  Sorrento (SRNE) Stock Is up 140% in Two Days. How Much Higher Can It Go? TipRanks
02:36PM  Sorrento Therapeutics Analyst Says Coronavirus Antibody Cocktail One Of Few Non-Vaccine Options Benzinga
02:05PM  Heres what it will take for the stock market to hit a new record within 2 months MarketWatch
01:35PM  'This is a wonderful time to invest:' market strategist Yahoo Finance
10:11AM  Why Sorrento Therapeutics Stock Is on Fire Today Motley Fool
08:36AM  Implied Volatility Surging for Sorrento Therapeutics (SRNE) Stock Options Zacks
May-16-20 08:41AM  Dow recovers to post modest gains despite dismal U.S retail sales data, tensions with China MarketWatch
May-15-20 04:13PM  Covid Report: The Trouble With Tiny Biotech's Coronavirus Cure Claim Investor's Business Daily +158.02%
01:45PM  Sorrento Therapeutics' stock soars on massive volume after upbeat report on COVID-19 antibody experiment MarketWatch
11:57AM  Sorrento Shares Double on Claim of a Potential Breakthrough Virus Drug TheStreet.com
11:53AM  Why Sorrento Therapeutics Is Skyrocketing Today Motley Fool
11:00AM  STI-1499, A Potent Anti-SARS-CoV-2 Antibody, Demonstrates Ability To Completely Inhibit In Vitro Virus Infection In Preclinical Studies PR Newswire
10:49AM  Sorrento Therapeutics Rips Higher, Coronavirus Antibody Shows 100% Inhibition In Experiment Benzinga
10:24AM  Price Over Earnings Overview: Sorrento Therapeutics Benzinga
May-13-20 12:30PM  Sorrento Therapeutics (SRNE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
May-08-20 11:51AM  Sorrento's stock jumps on antibody plans with Mount Sinai Health System MarketWatch +7.88%
11:09AM  Sorrento Surges on Effort to Make Covid-19 'Antibody Cocktail' TheStreet.com
Apr-15-20 08:52AM  Is the Options Market Predicting a Spike in Sorrento Therapeutics (SRNE) Stock? Zacks -8.21%
Apr-08-20 02:54PM  Sorrento Provides Manufacturing Support for COVID-19 Treatment; Whats Next? TipRanks
Apr-02-20 12:33PM  SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAL FOR COVID-19 BEGINS ENROLLING PATIENTS GlobeNewswire +16.76%
Apr-01-20 10:25AM  Analyst Impressed by Sorrentos COVID-19 Pipeline, Says Buy TipRanks -5.98%
Mar-31-20 02:01PM  SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES GlobeNewswire
Mar-25-20 10:00AM  Sorrento Launches Novel I-Cell COVID-19 Cellular Vaccine Program GlobeNewswire
Mar-24-20 09:32AM  SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB TO POTENTIALLY TREAT COVID-19 GlobeNewswire
Mar-23-20 09:30AM  Company News for Mar 23, 2020 Zacks
09:00AM  SORRENTO AND SMARTPHARM TO COLLABORATE TO DEVELOP NOVEL GENE-ENCODED ANTIBODY VACCINE INTENDED TO PROTECT AGAINST COVID-19 GlobeNewswire
Mar-20-20 09:25AM  Sorrento Plans Preclinical Testing Of 'COVIDTRAP' Protein To Treat New Coronavirus Benzinga +14.53%
07:00AM  SORRENTO DEVELOPS STI-4398 (COVIDTRAP PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19) GlobeNewswire
Mar-13-20 12:30PM  Earnings Preview: Sorrento Therapeutics (SRNE) Q4 Earnings Expected to Decline Zacks -7.03%
Mar-05-20 09:13AM  Are Options Traders Betting on a Big Move in Sorrento Therapeutics (SRNE) Stock? Zacks +8.41%
Mar-03-20 10:45AM  This Analyst Sees a 14-Bagger in Sorrento (SRNE) Stock TipRanks
Feb-27-20 03:30PM  Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial GlobeNewswire
06:00AM  Sorrento to Provide Corporate Update, Including DAR-T Cell Therapy Advances, at LEERINK Global Healthcare Conference GlobeNewswire
Feb-21-20 09:15AM  Sorrento Therapeutics CEO Dr. Ji to Present at LEERINK Partners 9th Global Healthcare Conference GlobeNewswire
Jan-29-20 07:00AM  Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection GlobeNewswire -6.17%
Jan-27-20 12:21PM  Sorrento Therapeutics rejects near $1 billion offer, shares fall Reuters -9.13%
08:45AM  Sorrento Rejects Takeover Offer Benzinga
07:00AM  Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences GlobeNewswire
07:00AM  Sorrento Board Rejects Latest Acquisition Proposal GlobeNewswire
Jan-10-20 10:59AM  All Bets Are Off for Amarin Stock InvestorPlace +39.59%
10:29AM  Sorrento surges on a near $1 billion takeout offer Reuters
09:03AM  Benzinga Pro's Top 5 Stocks To Watch For Fri., Jan. 10, 2020: LLY, JPM, SRNE, ELAN, TWTR Benzinga
08:30AM  Sorrento shares rise on private equity proposal MarketWatch
07:00AM  Sorrento Therapeutics, Inc. Received Non-Binding Acquisition Proposal GlobeNewswire
Jan-06-20 07:00AM  Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China GlobeNewswire
Dec-16-19 07:00AM  Sorrento Announces Dr. Robin Smith as New Member of the Board of Directors GlobeNewswire
Dec-09-19 07:00AM  Sorrento Announces New Board Member GlobeNewswire +8.24%
Dec-03-19 04:14PM  Sorrento (SRNE) Stock Has More Room to Run, Says Analyst TipRanks +9.06%
Nov-27-19 08:51AM  Implied Volatility Surging for Sorrento (SRNE) Stock Options Zacks
03:32AM  Sorrento Turns Down Two All-Cash Takeover Bids, Stock Jumps Zacks
Nov-26-19 11:25AM  Analysts See 700% Upside In Sorrento Therapeutics After Unsolicited Takeover Bid Benzinga
Nov-25-19 12:06PM  Sorrento (SRNE) Stock Has Over 700% Upside Potential, Says Analyst TipRanks +94.37%
07:52AM  Sorrento Therapeutics shares soar 25% after it rejects offer from two companies MarketWatch
07:47AM  UPDATE 1-Sorrento Therapeutics rejects all-cash takeout proposal; shares jump Reuters
07:12AM  Sorrento Therapeutics rejects all-cash takeout proposal Reuters
07:00AM  Sorrento Therapeutics, Inc. Received and Rejected Unsolicited All Cash Acquisition Proposal GlobeNewswire
Nov-12-19 07:05AM  Sorrento CEO to Present at Upcoming Investor Conferences GlobeNewswire
Nov-07-19 05:05PM  Sorrentto Therapeutics Inc (SRNE): Are Hedge Funds Right About This Stock? Insider Monkey +7.01%
Nov-06-19 07:37PM  Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences GlobeNewswire
Nov-01-19 10:30AM  Earnings Preview: Sorrento Therapeutics (SRNE) Q3 Earnings Expected to Decline Zacks +7.24%
Oct-15-19 10:36PM  Los Angeles Court Rejects Patrick Soon-Shiongs Attempt to Avoid Sorrento Litigation Allowing Arbitration Case to Move Forward GlobeNewswire
12:28PM  What Kind Of Shareholders Own Sorrento Therapeutics, Inc. (NASDAQ:SRNE)? Simply Wall St.
Oct-09-19 10:35AM  Sorrento Therapeutics Announces Closing of $25 Million Registered Direct Offering GlobeNewswire
Oct-07-19 02:35PM  Sorrento Therapeutics Announces $25 Million Registered Direct Offering GlobeNewswire -25.52%
Sep-30-19 07:00AM  Scilex Holding Company Strengthens Board of Directors with Appointment of Two Highly Accomplished Pharmaceutical and Biotechnology Executives, Scott Whitcup, M.D. and Elizabeth Czerepak GlobeNewswire
Sep-23-19 07:00AM  Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering GlobeNewswire
Aug-14-19 08:33AM  Those Who Purchased Sorrento Therapeutics (NASDAQ:SRNE) Shares Three Years Ago Have A 67% Loss To Show For It Simply Wall St.
Aug-01-19 10:33AM  Sorrento Therapeutics (SRNE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks -6.32%
Jul-29-19 10:12AM  Moving Average Crossover Alert: Sorrento Therapeutics Zacks
Jul-02-19 12:40PM  Sorrento Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Warrants GlobeNewswire
Jul-01-19 08:46AM  Implied Volatility Surging for Sorrento (SRNE) Stock Options Zacks
Jun-28-19 04:40PM  Why PG&E, Pier 1 Imports, and Sorrento Therapeutics Slumped Today Motley Fool -21.24%
12:18PM  Sorrento Therapeutics News: SRNE Stock Tanks on Equity Offering InvestorPlace
08:37AM  Sorrento Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock and Warrants GlobeNewswire
06:00AM  Sorrento Therapeutics Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire
Jun-19-19 11:51AM  Sorrento Therapeutics Shares Move On RTX Trial Update Benzinga
07:00AM  Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial GlobeNewswire
07:00AM  Sorrento Provides Updates on CD38 Immunotherapies and Implementation of Disruptive GMP Manufacturing for Off-The-Shelf Cell Therapy GlobeNewswire
Jun-14-19 07:00AM  Sorrento Therapeutics to Present at the JMP Securities Life Sciences Conference in New York (NY) GlobeNewswire
Jun-12-19 07:00AM  Sorrento to Explore Potential Initial Public Offering of Scilex Holding Company GlobeNewswire
Jun-10-19 07:00AM  Positive Feline Clinical Trial Outcome Motivates Sorrento Therapeutics to Accelerate Human IND Filing of Resiniferatoxin (RTX) for Prolonged Non-Opioid Control of Post-Amputation Neuropathic Pain GlobeNewswire
Jun-05-19 07:00AM  Scilex Holding Announces Strong ZTlido Sales Growth After Successful Post-Merger Integration GlobeNewswire
Jun-04-19 07:00AM  Sorrento Announces Cannabidiol (CBD) Global Joint Ventures and Commercial Strategic Partnerships GlobeNewswire +5.57%
May-29-19 01:03PM  Why Sorrento Therapeutics Is Getting Crushed Today Motley Fool -10.33%
May-21-19 06:25PM  Sorrento Therapeutics to Present at 20th Annual B. Riley FBR Investor Conference in Los Angeles (ca). GlobeNewswire
May-20-19 08:50AM  Options Traders Expect Huge Moves in Sorrento (SRNE) Stock Zacks
May-03-19 10:32AM  What's in Store for Sorrento (SRNE) This Earnings Season? Zacks
Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company's clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases. Further, it develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Additionally, the company engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. It has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, as well as a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento's COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith Robin LDirectorMar 05Buy2.2740,00090,89660,000Mar 05 01:58 PM